Compare Indonesia Energy Corporation Limited (INDO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Regeneron Pharmaceuticals Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.71 (market cap $42.62M), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 1792.6× Indonesia Energy Corporation Limited's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| INDO | REGN | |
|---|---|---|
Market Cap | $42.62M | $76.40B |
Volume | 60,371 | 626,381 |
Sector | Energy | Health |
52-Week High | $6.74 | $852.03 |
52-Week Low | $2.49 | $557.73 |
Typical Hold Time | 24 Days | 107 Days |
Enterprise Value | $37.56M | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $5.10 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from analysts, fundamental weaknesses and negative earnings trends pose significant risks. The stock's outlook depends on successful execution of drilling operations to improve financial performance. Investors should weigh high operational risks against potential growth from new production.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
